{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:44:27Z","timestamp":1793227467338,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jpeds.2021.08.079","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T05:19:04Z","timestamp":1630646344000},"page":"150-157.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory\u00a0Bowel Disease under Combination Therapy"],"prefix":"10.1016","volume":"240","author":[{"given":"Karen","family":"van Hoeve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim Sadat","family":"Seyed Tabib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Dreesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Tops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-7161","authenticated-orcid":false,"given":"Ann","family":"Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-0716","authenticated-orcid":false,"given":"Marc","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2021.08.079_bib1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.crohns.2014.04.005","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","article-title":"Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition","volume":"67","author":"Turner","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","article-title":"Novel targeted therapies for inflammatory bowel disease","volume":"38","author":"Coskun","year":"2017","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jpeds.2021.08.079_bib4","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2021.08.079_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2021.08.079_bib6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ibd.20927","article-title":"Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease","volume":"15","author":"Schnitzler","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib7","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2019.03.022","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the medical management of pediatric luminal Crohn's disease","volume":"157","author":"Mack","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2021.08.079_bib8","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1097\/MIB.0000000000001231","article-title":"Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window","volume":"23","author":"Papamichael","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.jpeds.2021.08.079_bib10","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","article-title":"IOIBD technical review on endoscopic indices for Crohn's disease clinical trials","volume":"65","author":"Vuitton","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jpeds.2021.08.079_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/apt.13948","article-title":"Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus","volume":"45","author":"Vuitton","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2021.08.079_bib12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2021.08.079_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MPG.0000000000002265","article-title":"Adequate infliximab exposure during induction predicts remission in paediatric patients with inflammatory bowel disease","volume":"68","author":"van Hoeve","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MPG.0000000000002486","article-title":"Improving post-induction anti-tumor necrosis factor therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"70","author":"Guido","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib15","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/MPG.0000000000002304","article-title":"Development of infliximab target concentrations during induction in pediatric Crohn disease patients","volume":"69","author":"Clarkston","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib16","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"van Hoeve","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/MPG.0000000000000239","article-title":"ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents","volume":"58","author":"Levine","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ibd.21493","article-title":"Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification","volume":"17","author":"Levine","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib19","first-page":"439","article-title":"Development and validation of a Pediatric Crohn's Disease Activity Index","volume":"12","author":"Hyams","year":"1991","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.gastro.2007.05.029","article-title":"Development, validation, and evaluation of a Pediatric Ulcerative Colitis Activity Index: a prospective multicenter study","volume":"133","author":"Turner","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2021.08.079_bib22","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1097\/MIB.0000000000000434","article-title":"An optimized anti-infliximab bridging enzyme-linked immunosorbent assay for harmonization of anti-infliximab antibody titers in patients with inflammatory bowel diseases","volume":"21","author":"Van Stappen","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib23","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/ajg.2010.143","article-title":"Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties","volume":"105","author":"Turner","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpeds.2021.08.079_bib24","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/ibd.20867","article-title":"Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI)","volume":"15","author":"Turner","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MPG.0000000000002112","article-title":"Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study","volume":"68","author":"Naviglio","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib26","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib27","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/MIB.0000000000000769","article-title":"Serum infliximab, antidrug antibodies, and tumor necrosis factor predict sustained response in pediatric Crohn's disease","volume":"22","author":"Stein","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib28","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MPG.0000000000002536","article-title":"Trough levels of infliximab at W6 are predictive of remission at W14 in pediatric Crohn disease","volume":"70","author":"Courbette","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jpeds.2021.08.079_bib29","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/ibd\/izy132","article-title":"Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn's disease","volume":"24","author":"Papamichael","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib30","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2021.08.079_bib31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cpt.2148","article-title":"Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn's disease","volume":"109","author":"Xiong","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2021.08.079_bib32","first-page":"jjaa161","article-title":"The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update","author":"van Rheenen","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jpeds.2021.08.079_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpeds.2021.08.079_bib34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.clinthera.2011.06.002","article-title":"Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials","volume":"33","author":"Fasanmade","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpeds.2021.08.079_bib35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/cells8060535","article-title":"Molecular profiling of inflammatory bowel disease: is it ready for use in clinical decision-making?","volume":"8","author":"Lee","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jpeds.2021.08.079_bib36","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaci.2017.11.024","article-title":"TNF-\u03b1-induced protein 3 (TNFAIP3)\/A20 acts as a master switch in TNF-\u03b1 blockade-driven IL-17A expression","volume":"142","author":"Urbano","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jpeds.2021.08.079_bib37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/mi.2014.124","article-title":"Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease","volume":"8","author":"Friedrich","year":"2015","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jpeds.2021.08.079_bib38","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/tpj.2014.19","article-title":"Associations between functional polymorphisms in the NF\u03baB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease","volume":"14","author":"Bank","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jpeds.2021.08.079_bib39","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/jid.2011.376","article-title":"TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis","volume":"132","author":"Tejasvi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jpeds.2021.08.079_bib40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1084\/jem.20090849","article-title":"TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis","volume":"207","author":"Noti","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpeds.2021.08.079_bib41","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41435-019-0056-1","article-title":"Intestinal glucocorticoid synthesis enzymes in pediatric inflammatory bowel disease patients","volume":"20","author":"Ahmed","year":"2019","journal-title":"Genes Immun"},{"key":"10.1016\/j.jpeds.2021.08.079_bib42","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.crohns.2013.11.007","article-title":"The lectin pathway of the complement system is downregulated in Crohn's disease patients who respond to anti-TNF-\u03b1 therapy","volume":"8","author":"Sandahl","year":"2014","journal-title":"J Crohns Colitis"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621008647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621008647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:10:09Z","timestamp":1758359409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347621008647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":41,"alternative-id":["S0022347621008647"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.08.079","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory\u00a0Bowel Disease under Combination Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.08.079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}